{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014263","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.817860+00:00","generated_at":"2026-06-24T05:19:20.725715+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus Q2 rev $26.8M, net loss $66.6M; ARC-8 PDAC data similar to historical chemo benchmarks; cash $1.27B","bullets":["Cash, cash equivalents and investments $1,271.1M at June 30, 2022, up from $681.3M at Dec 2021, driven by $725M Gilead payment.","Collaboration revenue $26.8M for Q2 2022 vs $9.5M YoY; net loss $66.6M vs $76.0M YoY.","ARC-8 interim analysis for quemliclustat in PDAC: data from randomized cohort similar to historical chemo benchmarks; Arcus and Gilead await mature data in 2023.","Four registrational Phase 3 trials of domvanalimab-based combinations ongoing or planned; ARC-7 topline disclosure expected H2 2022.","AB521 (HIF-2a inhibitor) Phase 1/1b to start Q3 2022; AB801 (AXL inhibitor) nominated; two new molecules expected in clinic in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014263","json":"https://secwatch.observer/filing/0000950170-22-014263.json","markdown":"https://secwatch.observer/filing/0000950170-22-014263.md","text":"https://secwatch.observer/filing/0000950170-22-014263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022014263/0000950170-22-014263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022014263/rcus-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:19:20.725715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}